These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 30745542)

  • 1. Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
    Sasaki T; Nakamura K; Naito S
    Int Heart J; 2019 Mar; 60(2):466-469. PubMed ID: 30745542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oversensing issues leading to device extraction: When subcutaneous implantable cardioverter-defibrillator reached a dead-end.
    Noel A; Ploux S; Bulliard S; Strik M; Haeberlin A; Welte N; Marchand H; Klotz N; Ritter P; Haïssaguerre M; Bordachar P
    Heart Rhythm; 2020 Jan; 17(1):66-74. PubMed ID: 31295585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple appropriate and spurious defibrillator shocks in a patient with right ventricular cardiomyopathy.
    Strohmer B; Schernthaner C; Pichler M
    Int J Cardiol; 2005 Jul; 102(2):363-6. PubMed ID: 15982515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractoriness to subcutaneous implantable cardioverter defibrillator after frequent therapies for ventricular fibrillation storms in a Brugada syndrome case.
    Nakao Y; Suenari K; Yamashiro K; Nakagawa H; Shiode N
    BMC Cardiovasc Disord; 2020 Mar; 20(1):134. PubMed ID: 32169057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD.
    Corzani A; Ziacchi M; Biffi M; Diemberger I; Martignani C; Boriani G
    Indian Heart J; 2015; 67(1):56-9. PubMed ID: 25820052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.
    Migliore F; Mattesi G; De Franceschi P; Allocca G; Crosato M; Calzolari V; Fantinel M; Ortis B; Facchin D; Daleffe E; Fabris T; Marras E; De Lazzari M; Zanon F; Marcantoni L; Siciliano M; Corrado D; Iliceto S; Bertaglia E; Zecchin M
    J Cardiovasc Electrophysiol; 2019 Jun; 30(6):854-864. PubMed ID: 30827041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure.
    Spencker S; Coban N; Koch L; Schirdewan A; Müller D
    Europace; 2009 Apr; 11(4):483-8. PubMed ID: 19103654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management.
    Olde Nordkamp LR; Brouwer TF; Barr C; Theuns DA; Boersma LV; Johansen JB; Neuzil P; Wilde AA; Carter N; Husby M; Lambiase PD; Knops RE
    Int J Cardiol; 2015 Sep; 195():126-33. PubMed ID: 26026928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of issues detected by an ICD diagnostic alert that utilizes far-field electrograms: Clinical implications.
    Koneru JN; Kaszala K; Bordachar P; Shehata M; Swerdlow C; Ellenbogen KA
    Heart Rhythm; 2015 May; 12(5):957-67. PubMed ID: 25640632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter investigation of an implantable cardioverter-defibrillator algorithm to detect oversensing.
    Welte N; Strik M; Eschalier R; Mondoly P; Defaye P; Frontera A; Ritter P; Haïssaguerre M; Ploux S; Koneru J; Ellenbogen KA; Bordachar P
    Heart Rhythm; 2017 Jul; 14(7):1008-1015. PubMed ID: 28323174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Subcutaneous Cardioverter Defibrillator in Patients at High Risk of Sudden Cardiac Death　- Primary Japanese Experience.
    Sasaki S; Tomita H; Tsurugi T; Ishida Y; Shoji Y; Nishizaki K; Kinjo T; Endo T; Nishizaki F; Hanada K; Sasaki K; Horiuchi D; Kimura M; Higuma T; Okamatsu H; Tanaka Y; Koyama J; Okumura K
    Circ J; 2018 May; 82(6):1546-1551. PubMed ID: 29643282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management.
    Kooiman KM; Knops RE; Olde Nordkamp L; Wilde AA; de Groot JR
    Heart Rhythm; 2014 Mar; 11(3):426-34. PubMed ID: 24321235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of myopotential induction in subcutaneous implantable cardioverter-defibrillator patients: Is the oversensing issue really solved?
    van den Bruck JH; Sultan A; Plenge T; Seuthe K; Mödder T; Iliadis C; Stern D; Blankenheim T; Steven D; Lüker J
    Heart Rhythm; 2019 Oct; 16(10):1523-1530. PubMed ID: 31048064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myopotential Oversensing Is a Major Cause of Inappropriate Shock in Subcutaneous Implantable Defibrillator in Japan.
    Tsutsui K; Kato R; Asano S; Ikeda Y; Mori H; Tawara M; Tanaka S; Hasegawa S; Nakano S; Iwanaga S; Muramatsu T; Matsumoto K
    Int Heart J; 2020 Sep; 61(5):913-921. PubMed ID: 32921668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inappropriate discharges from an intravenous implantable cardioverter defibrillator due to T-wave oversensing.
    Washizuka T; Chinushi M; Kasai H; Watanabe H; Tagawa M; Hosaka Y; Abe A; Aizawa Y
    Jpn Circ J; 2001 Jul; 65(7):685-7. PubMed ID: 11446507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA; Sharma S; Pelchovitz DJ; Bhave PD; Rhyner J; Verma N; Arora R; Chicos AB; Kim SS; Lin AC; Passman RS; Knight BP
    Heart Rhythm; 2014 Aug; 11(8):1361-6. PubMed ID: 24755323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators.
    Ishida Y; Payne JE; Field ME; Gold MR
    J Cardiovasc Electrophysiol; 2020 May; 31(5):1195-1201. PubMed ID: 32128931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.